Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Update From Conclusion of COVID-19 Vaccine Study

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Feb 17, 2021 6:55pm

135 Views

Post# 32591569

RE:RE:RE:RE:Update From Conclusion of COVID-19 Vaccine Study

Somebody was buying today !!!!

trinimetal wrote: He couldn't get it right this time but has the audacity to say SP "MAY" provide long term efficacy for mutations? Look STFU David Goren. We aren't falling for your bull shiit this time.

<< Previous

Bullboard Posts

Next >>

Shopify stock hits year-high on Q3 results